Macimorelin    (DrugBank: Macimorelin)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
78下垂体前葉機能低下症7

78. 下垂体前葉機能低下症 [臨床試験数:462,薬物数:346(DrugBank:45),標的遺伝子数:41,標的パスウェイ数:80
Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 462 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-001988-23-PL
(EUCTR)
19/04/201923/01/2019A clinical study with macimorelin acetate comparing three doses in their safety and tolerability in children with suspected growth hormone deficiency (GHD)Open label, group comparison, dose escalation trial to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of macimorelin acetate after single oral dosing of 0.25 mg/kg, 0.5 mg/kg, and 1 mg/kg in pediatric patients with suspected growth hormone deficiency (GHD) Diagnosis of Growth Hormone Deficiency
MedDRA version: 21.0;Level: LLT;Classification code 10073227;Term: Growth hormone stimulation test;System Organ Class: 100000004848;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Trade Name: Macrilen
Product Name: macimorelin
INN or Proposed INN: macimorelin
Other descriptive name: MACIMORELIN ACETATE
Aeterna Zentaris GmbHNULLNot RecruitingFemale: yes
Male: yes
24Phase 2Serbia;Belarus;Hungary;Poland;Ukraine;Russian Federation
2EUCTR2018-001988-23-HU
(EUCTR)
07/11/201805/09/2018A clinical study with macimorelin acetate comparing three doses in their safety and tolerability in children with suspected growth hormone deficiency (GHD)Open label, group comparison, dose escalation trial to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of macimorelin acetate after single oral dosing of 0.25 mg/kg, 0.5 mg/kg, and 1 mg/kg in pediatric patients with suspected growth hormone deficiency (GHD) Diagnosis of Growth Hormone Deficiency
MedDRA version: 20.0;Level: LLT;Classification code 10073227;Term: Growth hormone stimulation test;System Organ Class: 100000004848 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Aeterna Zentaris GmbHNULLNot Recruiting Female: yes
Male: yes
24Phase 2Serbia;Hungary;Poland;Ukraine;Russian Federation
3EUCTR2015-002337-22-PL
(EUCTR)
12/04/201601/02/2016Comparison of the substance macimorelin (drinking solution) with insulin (injection) to confirm that it works as diagnostic test for lacking growth hormone in adultsConfirmatory validation of oral macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the diagnosis of Adult Growth Hormone Deficiency (AGHD) in comparison with the Insulin Tolerance Test (ITT) - Validation of macimorelin as a test for Adult Growth Hormone Deficiency Diagnosis of Adult Growth Hormone Deficiency (AGHD);Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]Aeterna Zentaris GmbHNULLNot Recruiting Female: yes
Male: yes
110Phase 3Serbia;France;United States;Spain;Poland;Austria;Germany;Italy;United Kingdom
4EUCTR2015-002337-22-DE
(EUCTR)
19/01/201609/11/2015Comparison of the substance macimorelin (drinking solution) with insulin (injection) to confirm that it works as diagnostic test for lacking growth hormone in adultsConfirmatory validation of oral macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the diagnosis of Adult Growth Hormone Deficiency (AGHD) in comparison with the Insulin Tolerance Test (ITT) - Validation of macimorelin as a test for Adult Growth Hormone Deficiency Diagnosis of Adult Growth Hormone Deficiency (AGHD);Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]Product Name: Macimorelin
Product Code: AEZS-130
INN or Proposed INN: Macimorelin acetate
Other descriptive name: MACIMORELIN ACETATE
Product Name: Insulin
INN or Proposed INN: Insulin
Other descriptive name: INSULIN
Aeterna Zentaris GmbHNULLNot RecruitingFemale: yes
Male: yes
110Phase 3Serbia;France;United States;Poland;Spain;Austria;Germany;Italy;United Kingdom
5EUCTR2015-002337-22-AT
(EUCTR)
10/12/201530/10/2015Comparison of the substance macimorelin (drinking solution) with insulin (injection) to confirm that it works as diagnostic test for lacking growth hormone in adultsConfirmatory validation of oral macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the diagnosis of Adult Growth Hormone Deficiency (AGHD) in comparison with the Insulin Tolerance Test (ITT) - Validation of macimorelin as a test for Adult Growth Hormone Deficiency Diagnosis of Adult Growth Hormone Deficiency (AGHD);Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]Product Name: Macimorelin
Product Code: AEZS-130
INN or Proposed INN: Macimorelin acetate
Other descriptive name: MACIMORELIN ACETATE
Product Name: Insulin
INN or Proposed INN: Insulin
Other descriptive name: INSULIN
Aeterna Zentaris GmbHNULLNot RecruitingFemale: yes
Male: yes
110Phase 3Serbia;France;United States;Poland;Spain;Austria;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2015-002337-22-GB
(EUCTR)
08/12/201528/10/2015Comparison of the substance macimorelin (drinking solution) with insulin (injection) to confirm that it works as diagnostic test for lacking growth hormone in adultsConfirmatory validation of oral macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the diagnosis of Adult Growth Hormone Deficiency (AGHD) in comparison with the Insulin Tolerance Test (ITT) - Validation of macimorelin as a test for Adult Growth Hormone Deficiency Diagnosis of Adult Growth Hormone Deficiency (AGHD);Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]Aeterna Zentaris GmbHNULLNot Recruiting Female: yes
Male: yes
110Phase 3Serbia;France;United States;Poland;Spain;Austria;Germany;Italy;United Kingdom
7NCT02558829
(ClinicalTrials.gov)
December 3, 201521/9/2015Validation of Macimorelin as a Test for Adult Growth Hormone DeficiencyConfirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)Growth Hormone Deficiency With Pituitary AnomaliesDrug: Macimorelin;Drug: InsulinAEterna ZentarisNULLCompleted18 Years65 YearsAll157Phase 3United States;Austria;France;Germany;Italy;Poland;Serbia;Spain;United Kingdom